Basic information
-
Name
Doramapimod, p38 MAP kinase inhibitor
-
Price
427 EUR
-
Size
25 mg
-
Catalog number
SIH-442-25MG
Detailed information
Stock availabilitIn Stock
In Stock
CAS number
285983-48-4
Description
p38 MAP kinase inhibitor
Molecular weight
527,7 g/mol
Primary research fields
Cell Signaling, Cancer, Apoptosis, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors
Other name
JNK Inhibitor XVII, BIRB796, 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
Product category
Small Molecules
Product type
Inhibitor
Chemical formula
C31H37N5O3
Origin
Synthetic
Purity pourcentage
≥99% (HPLC)
Soluble in
Soluble in DMSO
Physical appearance
White solid
Storage recommendations
-20ºC
Shipping recommendations
Shipped Ambient
Safety information
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
PubChem number
156422
Scientific context
Doramapimod is a highly potent and selective inhibitor of p38α MAPK. It specifically blocks TNFα release.
Bibliography
1. Pargellis C., et al. (2002). Nat Structural Biol. 9(4): 268–272.
Release date
1-Oct-2014
PubMed number
Refer to PubMed
Tested applications
To be tested
Tested reactivity
To be tested
Representative figure legend
Chemical structure of Doramapimod (SIH-442), a p38 MAP kinase inhibitor. CAS #: 285983-48-4. Molecular Formula: C31H37N5O3. Molecular Weight: 527.7 g/mol. Chemical structure of Doramapimod, a p38 MAP kinase inhibitor (SIH-442). CAS # 285983-48-4. Molecular Formula: C31H37N5O3.
Warning information
Non-hazardous
Country of production
Canada
Total weight (kg)
0.25
Net weight (g)
0.025
Additional description
Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.